Puma Biotechnology, Inc. (PBYI:NASDAQ) closed at $9.83 on October 16, 2026, down 6.56% on the day. The stock trades 8.3% below its 52-week high of $10.72 and 114.6% above its 52-week low of $4.58. Over the past year, it gained 79.7%. Puma Biotechnology, Inc. is part of the Health Care sector (Major Pharmaceuticals).
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -4.47% | +3.26% | +18.43% | +33.38% | +79.71% |
In 252 trading sessions since October 16, 2025, PBYI closed higher on 137 days (54%). Its best day was November 7, 2025 (+22.24%) and its worst was February 27, 2026 (-25.00%). The stock moved 10% or more in a single session 4 times. It opened at least 5% above the previous day's high 1 time.
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Find more stocks like PBYI with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.